IMMUNOLOGY TEXTBOOK - Mercury Podillia 2013

CORE PRINCIPLES IN THE MANAGEMENT OF IMMUNODEFICIENCY

Empiric Antibacterial Therapy in Immunodeficient States

In The Setting of immune deficiency, combination therapy with agents active against Gram-negative Bacteria is indicated—for example, an aminoglycoside paired with a broad-spectrum penicillin (such as ticarcillin), a third- or fourth-generation cephalosporin (such as ceftazidime), or a monobactam. Penicillins combined with beta-lactamase inhibitors, carbapenems (imipenem/cilastatin), and Monobactams (aztreonam) are prescribed if beta-lactam resistance is prevalent in the local area or if the patient is known to be infected with a resistant strain. For patients with foreign bodies (such as vascular catheters), Antibiotics active against Gram-positive bacteria (Staphylococcus epidermidis, Staphylococcus aureus, enterococci) should be administered: anti-staphylococcal Semisynthetic penicillins (oxacillin), or vancomycin if There is a significant risk of infection with methicillin-resistant Gram-positive bacteria. Antifungal agents should be added to broad-spectrum antibiotic regimens. Once positive culture results and susceptibility data for the isolated pathogen become available, the Treatment regimen should be reassessed.

When selecting an antibiotic, clinicians must consider both local pathogen susceptibility patterns and the specific clinical context. If the causative agent is known, one can anticipate its likely Antibiotic Resistance profile even before formal susceptibility testing is completed. This is particularly crucial in immunodeficient states complicated by nosocomial infections (in patients with vascular catheters and other foreign bodies) as well as community-acquired infections. It is essential to monitor serum concentrations of certain antibiotics (such as Aminoglycosides and vancomycin), especially in critically ill patients with impaired renal function and altered volumes of distribution, which can delay drug elimination (prolonging the half-life, T1/2).

All patients presenting with neutropenia (neutrophil count below 0.5 x 109/L) and fever should initiate antibacterial therapy immediately. Priority is given to broad-spectrum bactericidal antibiotics administered intravenously at maximal therapeutic doses. Empiric therapy is also warranted in afebrile neutropenic patients who exhibit clinical signs of infection. Various antibacterial treatment regimens may be employed.

Monotherapy (using ceftazidime, cefepime, or carbapenems) is less effective than combination antibiotic therapy in immunodeficient states, as these agents lack sufficient activity against opportunistic infections and enterococci.

The combination of antipseudomonal β-lactams—including inhibitor-protected agents (ticarcillin/clavulanate, piperacillin/tazobactam, ceftazidime, cefoperazone, cefoperazone/sulbactam, cefepime, carbapenems)—and third-generation aminoglycosides (amikacin, netilmicin) offers advantages due to additive or synergistic effects, anti-anaerobic activity, and a reduced likelihood of selecting resistant strains; however, its primary drawbacks include nephrotoxicity, ototoxicity, and the risk of hypokalemia.

The combination of two β-lactam antibiotics (such as piperacillin + ceftazidime) demonstrates insufficient activity against S. aureus and P. aeruginosa.

In healthcare facilities with a high incidence of Infections caused by Gram-positive microorganisms, initial therapy for patients with risk factors should include a combination of vancomycin and ceftazidime. Risk factors include: symptoms of catheter-related infection; severe mucosal damage (mucositis) resulting from Chemotherapy; prior antibiotic prophylaxis with fluoroquinolones; and established colonization with penicillin- and cephalosporin-resistant S. pneumoniae.

The efficacy of ongoing antibiotic therapy is evaluated after 3 days based on the persistence or resolution of fever. Once the fever resolves and the pathogen is identified, the treatment regimen may be adjusted to provide optimal therapy with minimal risk of adverse reactions and the lowest treatment cost. Antibiotic therapy is continued for up to 7 days or until pathogen eradication and the resolution of infection symptoms. In the presence of neutropenia, it is desirable for the neutrophil count to exceed 0.5 x 109/L by the time antibiotics are discontinued.

If microbiological test results are negative, empiric antibacterial therapy should be continued for 7 days. In compliant patients without overt signs of infection and with negative Blood cultures, a transition to oral therapy (amoxicillin/clavulanate + ciprofloxacin) can be made after 2 days.

Persistence of fever for more than 3 days despite antibacterial therapy may indicate: a non-bacterial infection; the presence of antibiotic-resistant microorganisms; The Development of a secondary infection; inadequate serum and tissue concentrations of the antibiotic; or a drug fever of allergic origin.

In some cases, even with optimal antibacterial therapy, the resolution of fever occurs on days 4–5; therefore, a thorough clinical evaluation of the patient should be performed.

If fever persists on days 4–7 and there is no Evidence of the aforementioned causes of initial treatment failure, the following alternatives may be considered: 1) continuing the initial therapy, 2) stopping or adding antibacterial drugs, or 3) adding an antifungal agent (itraconazole, intravenous fluconazole) with or without modifying the baseline antibiotic regimen.

If the patient's condition has not deteriorated, it is advisable to continue the current therapy. Should the disease progress, the initial regimen must be modified. For instance, if Corynebacterium spp., enterococci, or streptococci are isolated, or if Signs of Life-threatening Sepsis appear, The addition of vancomycin is warranted.

Patients who remain febrile for 1 week despite the administration of broad-spectrum antibiotics in adequate doses should receive antifungal therapy. The duration of treatment is determined by the severity of the infection (ranging from 2 weeks to 6 months).

For immunomodulatory purposes during and following combination antibiotic therapy, the administration of intravenous immunoglobulin is recommended: at THE START OF treatment, a loading dose of 1.2–1.5 g/kg per month, given in 4–5 infusions at 5- to 7-day intervals to achieve a normal age-matched serum IgG concentration. Maintenance therapy consists of 0.4 g/kg every 3–4 weeks for humoral immunodeficiency. Growth factors (filgrastim, neupogen) are used in cases of neutropenia and severe infections, while interferon-gamma is indicated for severe infections. Patients with immunodeficient states benefit from continuous prophylactic therapy using agents such as cotrimoxazole (biseptol), fluoroquinolones, or macrolides.